Summary
LY 186641 is a diarylsulfonylurea with a broad spectrum antitumor activity against both murine and human solid tumors. We report here the results of a phase II trial of LY 186641 in advanced renal cell adenocarcinoma.
The drug was administered orally, once daily for 2 weeks, every 21 days at a 700 mg/m2/d dose. Sixteen patients were enrolled in this phase II trial; 12 males, 4 females, with a median age of 58 years. All patients had progressive measurable metastatic disease. The primary tumor was surgically removed in all but one patient. Three patients were previously treated by biologic response modifiers (BRMs). A total of 72 courses were administered. The most common side effects were methemoglobulinemia (MetHgb) and anemia which occurred in 13 and 10 patients respectively. The MetHgb did not exceed 15%, and only 3 patients required blood transfusion for grade 3 (2 patients) and grade 4 (1 patient) anemia. Reversible hepatotoxicity was observed in 3 patients.
There were one pathological complete response, seven stable disease and 8 progressive disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Grindey GB: Identification of Diarylsulfonylureas as novel anticancer drugs. Proc Am Assoc Cancer Res 29:535, 1988
Grindey GB, Boder GB, Grossman CS, Howbert JJ, Poore GA, Show WN, Todd GC, Worzalla JF. Further development of Diarylsulfonylureas as novel anticancer drugs. Proc Am Assoc Cancer Res 28:309, 1987
Houghton PJ, Houghton JA, Myers I, Cheshire P, Howbert JS, Grindey GB: Evaluation of N-(5-indanylsulfonyl)-N1-4 Chlorophenyl-urea against xenografts of pediatric rhabolomyosarcoma. Cancer Chemother Pharmacol 25:48–87, 1989
Armand JP, Recondo G, Gouyette A, Belerahdek M, Bonnay M, Chabot G, L'homme C: Phase I and pharmacokinetic study of LY 186641 administered daily for 2 weeks every 21 days. Inv New Drugs 7:423, 1989
Taylor CW, Alberts DS, Ketcham MA, Satterlee WG, Holdsworth MT, Plezia PM, Peng YM, McCloskey TM, Roe DJ, Hamilton M, Saluron SE: Clinical pharmacology of a novel Diarylsulfonylurea anticancer agent. J Clin Oncol 7:1733–1740, 1989
O'Brien M, Hardy J, Tan S, Walling J, Peters B, Hatty S, Wiltshaw E: A phase II study of sulfonur, a novel sulfonurea, in recurrent epithelial ovarian cancer. Cancer Chemother Pharmacol 30:245–248, 1992
World Health Organisation. WHO handbook for reporting results of cancer treatment. WHO offset publication 40. Geneva: WHO, 1979
Smith RP, Oison MV: Drug induced methemoglobinemia. Semin Hematol 10:253–268, 1973
Hall AH, Kulig KW, Rumach BH: Drug and chemicalinduced methaemoglobinaemia, clinical features and management. Med Toxicol 1:253–260, 1986
Ritchie AW, Dekernion JB: The natural history and clinical features of renal carcinoma. Semin Nephrol 7:131–139, 1987
Droz JP, Theodore C, Ghosn M, Lupera H, Piot G, De Forges A, Klink M, Rouesse J, Amiel JL: Twelve-year experience with chemotherapy in adult metastatic renal cell carcinoma at the Institut Gustave Roussy. Semin Surg Oncol 4:97–99, 1988
Finey R: An evaluation of post-operative radiotherapy in hypernephroma treatment. A clinical trial. Cancer 32:1332–1340, 1973
Eisenhauer EA, Silver HK, Venner PM, Thirlwell MP, Weinerman B, Coppin CM: Phase II study of high dose weekly intravenous human lymphoblastoid Interferon in renal cell carcinoma. A study of the National Cancer Institute of Canada Clinical Trials Group. Br J Cancer 55:541–542, 1987
Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp C, White D: Experience with the use of high dose Interleukin 2 in the treatment of 652 cancer patients. Ann Surgery 210:474–485, 1989
Hercend T, Farace F, Baume D. Immunotherapy with lymphokine-activated matural killer cells and recombinant Interleukin 2: a feasability trial in metastatic renal cell carcinoma. J Biol Response Modifiers 9:546–555, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mahjoubi, M., Kattan, J., Bonnay, M. et al. Phase II trial of LY 186641 in advanced renal cancer. Invest New Drugs 11, 323–328 (1993). https://doi.org/10.1007/BF00874431
Issue Date:
DOI: https://doi.org/10.1007/BF00874431